



# AMURA

## Press Release

**Amura announces that its lead compounds for osteoporosis and bone metastasis have demonstrated good *in vivo* safety profiles in repeat-dose toxicity study.**

**Cambridge, U.K. – 03<sup>rd</sup> May 2007**

Amura Holdings Limited ("Amura") today announced that its lead compounds for osteoporosis and bone metastasis have demonstrated good *in vivo* safety profiles in a rodent seven-day repeat-dose toxicity study. The compounds were well tolerated and no adverse histological effects were noted.

Cathepsin K, which is a member of a large family (CAC1) of cysteine peptidases, is an enzyme which breaks down the collagen bone matrix as part of a normal biological process. In disease conditions such as osteoporosis, the relative cathepsin K activity is increased, thereby increasing bone degradation. Drugs that inhibit cathepsin K could provide a novel method for the treatment of osteoporosis and/or bone metastasis.

Amura's compounds were derived from the proprietary AMcore™ scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Cysteine peptidases are involved in several diseases and the AMcore™ scaffold provides a powerful platform for discovery of drugs with potential utility against a range of commercially attractive therapeutic targets. The company has further programmes selectively targeting cathepsin S and other members of this family.

Amura intends to out-license its cathepsin K inhibitor products for clinical development.

Additional information about Amura is available at the company website: <http://www.amura.co.uk/>

### Contact:

Dr Dan Roach  
Avlar BioVentures Limited

☎ +44 (0)1954 211515  
☎ +44 (0)1954 211516  
✉ DRoach@avlar.com